Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Belite Bio (BLTE) Is Up 9.0% After FDA Grants Priority Review To Tinlarebant Stargardt NDA

4 September 2026 · By · Wire by Fusion42

Published

4 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at simplywall.st →

◆ Verified

Fusion42 · 6 September 2026 · Fusion42 review

The FDA has granted priority review to Belite Bio's new drug application for tinlarebant to treat Stargardt disease type 1, setting a PDUFA decision date for February 12, 2027, while the company advances commercial preparations targeting 53,000 U.S. patients.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Belite Bio's upcoming FDA decision creates a critical regulatory deadline that frames your product launch timeline and investment window. Build your commercial strategy now to capture a market of over 50,000 patients before competitors enter.

◆ Coverage

1 source · 4 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-priority-reviewrare-diseasestargardtdrug-launchcommercialization